for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Emergent Biosolutions Inc

EBS

Latest Trade

115.10USD

Change

3.86(+3.47%)

Volume

873,299

Today's Range

111.48

 - 

119.63

52 Week Range

39.11

 - 

119.63

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
111.24
Open
111.68
Volume
873,299
3M AVG Volume
18.04
Today's High
119.63
Today's Low
111.48
52 Week High
119.63
52 Week Low
39.11
Shares Out (MIL)
105.33
Market Cap (MIL)
5,832.06
Forward P/E
24.91
Dividend (Yield %)
--

Next Event

Q3 2020 Emergent BioSolutions Inc Earnings Release

Latest Developments

More

Emergent Biosolutions Reports Q2 Adj. EPS Of $1.98

Emergent Biosolutions Signs Agreement With Astrazeneca To Expand Manufacturing For COVID-19 Vaccine Candidate

Mount Sinai Health System, Emergent Biosolutions, And Immunotek Bio Centers Collaborate To Develop Emergent's Covid-19 Hyperimmune Globulin Product Candidate With U.S. DoD

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Emergent Biosolutions Inc

Emergent BioSolutions Inc. is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs). The PHTs operates through two categories: Chemical, Biological, Radiological and Nuclear, as well as explosive-related threats and emerging infectious diseases. It operates through four business units: Vaccines and Anti-infectives; Antibody Therapeutics; Devices, and Contract Manufacturing. Vaccines and Anti-infectives business unit consists of BioThrax, which is for the general use prophylaxis and post-exposure prophylaxis of anthrax disease. Devices business unit consists of marketed products, such as Reactive Skin Decontamination Lotion Kit (RSDL) and Trobigard (atropine sulfate, obidoxime chloride).

Industry

Biotechnology & Drugs

Contact Info

400 Professional Dr Ste 400

GAITHERSBURG, MD

20879-3457

United States

+1.240.6313200

https://emergentbiosolutions.com/

Executive Leadership

Fuad El-Hibri

Executive Chairman of the Board

Robert G. Kramer

President, Chief Executive Officer, Director

Richard S. Lindahl

Chief Financial Officer, Executive Vice President, Treasurer

Katherine Strei

Executive Vice President, Human Resources and Communications, Chief Human Resources Officer

Atul Saran

Executive Vice President, Corporate Development, General Counsel and Corporate Secretary

Key Stats

1.71 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.6K

2018

0.8K

2019

1.1K

2020(E)

1.4K
EPS (USD)

2017

1.900

2018

2.330

2019

2.910

2020(E)

5.348
Price To Earnings (TTM)
34.63
Price To Sales (TTM)
4.63
Price To Book (MRQ)
4.91
Price To Cash Flow (TTM)
20.63
Total Debt To Equity (MRQ)
65.67
LT Debt To Equity (MRQ)
63.24
Return on Investment (TTM)
8.12
Return on Equity (TTM)
7.11

Latest News

Latest News

Emergent signs $174 million deal to make AstraZeneca's potential COVID-19 vaccine

Emergent BioSolutions Inc said on Monday it signed a $174 million agreement with AstraZeneca to develop and manufacture the British drugmaker's COVID-19 vaccine candidate.

Emergent signs $174 mln deal to make AstraZeneca's potential COVID-19 vaccine

Emergent BioSolutions Inc said on Monday it signed a $174 million agreement with AstraZeneca to develop and manufacture the British drugmaker's COVID-19 vaccine candidate.

Emergent to partner with Mount Sinai for potential plasma-derived COVID-19 therapy

Emergent BioSolutions Inc said on Wednesday it would jointly develop and run trials for its antibody product derived from plasma of recovered COVID-19 patients as a potential treatment with the Mount Sinai Health System.

BRIEF-Mount Sinai Health System, Emergent Biosolutions, And Immunotek Bio Centers Collaborate To Develop Emergent's Covid-19 Hyperimmune Globulin Product Candidate With U.S. DoD

* MOUNT SINAI HEALTH SYSTEM, EMERGENT BIOSOLUTIONS, AND IMMUNOTEK BIO CENTERS FORM COLLABORATION TO DEVELOP EMERGENT'S COVID-19 HYPERIMMUNE GLOBULIN (COVID-HIG) PRODUCT CANDIDATE WITH U.S. DEPARTMENT OF DEFENSE FUNDING

Emergent signs five-year deal backing J&J COVID-19 vaccine

Emergent BioSolutions Inc <EBS.N> said on Monday it signed a five-year contract to make the drug substance used in Johnson & Johnson's <JNJ.N> COVID-19 vaccine candidate, adding to a series of deals likely to put it at the heart of future global vaccine production.

BRIEF-Emergent Biosolutions Says Will Begin Providing Large-Scale Drug Substance Manufacturing For Johnson & Johnson's Adenovirus-Based Covid-19 Vaccine In 2021

* EMERGENT BIOSOLUTIONS SIGNS FIVE-YEAR AGREEMENT FOR LARGE-SCALE DRUG SUBSTANCE MANUFACTURING FOR JOHNSON & JOHNSON’S LEAD COVID-19 VACCINE CANDIDATE

Emergent to make drug substance for J&J's COVID-19 vaccine candidate

Emergent BioSolutions Inc said on Monday it has signed a five-year pact to make the drug substance used in Johnson & Johnson's COVID-19 vaccine candidate, in a deal valued at about $480 million for the first two years.

BRIEF-Emergent Biosolutions To Invest $75 Mln In Canton Site And Expand Viral Vector And Gene Therapy Capability

* EMERGENT BIOSOLUTIONS TO INVEST $75 MILLION IN CANTON SITE AND EXPAND VIRAL VECTOR AND GENE THERAPY CAPABILITY

BRIEF-Emergent Biosolutions To Become U.S. Manufacturing Partner For Astrazeneca's Covid-19 Vaccine Candidate

* EMERGENT BIOSOLUTIONS SIGNS AGREEMENT TO BE U.S. MANUFACTURING PARTNER FOR ASTRAZENECA’S COVID-19 VACCINE CANDIDATE

Emergent BioSolutions signs $87 mln deal to make AstraZeneca's COVID-19 vaccine in U.S.

Emergent BioSolutions Inc said on Thursday it signed a $87 million deal to make AstraZeneca Plc's experimental COVID-19 vaccine in the United States, as the British drugmaker looks to ramp up its efforts to bring a vaccine to the market.

BRIEF-Emergent Biosolutions Statement On U.S. District Court Decision

* EMERGENT BIOSOLUTIONS STATEMENT ON U.S. DISTRICT COURT DECISION

U.S. awards new $628 million contract to boost output of potential COVID-19 vaccine

The U.S. government on Monday entered into a $628 million contract with drugmaker Emergent BioSolutions <EBS.N> to boost manufacturing capacity for a potential COVID-19 vaccine.

U.S. awards new $628 mln contract to boost output of potential COVID-19 vaccine

The U.S. government on Monday entered into a $628 million contract with drugmaker Emergent BioSolutions to boost manufacturing capacity for a potential COVID-19 vaccine.

BRIEF-HHS - Emergent To Commit Manufacturing Capacity For Production Of Covid-19 Vaccine Candidates

* HHS ADDS $628 MILLION TO CONTRACT WITH EMERGENT BIOSOLUTIONS TO SECURE CDMO MANUFACTURING CAPACITY FOR OPERATION WARP SPEED

BRIEF-Emergent Biosolutions Joins U.S. Govt's Warp Speed Program For Covid-19

* EMERGENT BIOSOLUTIONS JOINS U.S. GOVERNMENT’S WARP SPEED PROGRAM IN LANDMARK PUBLIC-PRIVATE CDMO PARTNERSHIP FOR COVID-19 VACCINE DEVELOPMENT AND MANUFACTURING

BRIEF-Emergent Biosolutions Through Unit Received Contract Modification From Office Of Assistant Secretary For Preparedness And Response

* EMERGENT BIOSOLUTIONS - THROUGH UNIT RECEIVED CONTRACT MODIFICATION FROM OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE

J&J strikes deal with Emergent BioSolutions on coronavirus vaccine manufacturing

Johnson & Johnson said on Thursday it had struck a deal with Emergent BioSolutions Inc to use its manufacturing facilities to help in an effort to make more than 1 billion doses of a vaccine it is testing to stop the novel coronavirus.

BRIEF-Emergent Biosolutions Signs Agreement To Be U.S. Manufacturing Partner For J&J's Lead Vaccine Candidate For COVID-19

* EMERGENT BIOSOLUTIONS SIGNS AGREEMENT TO BE U.S. MANUFACTURING PARTNER FOR JOHNSON & JOHNSON’S LEAD VACCINE CANDIDATE FOR COVID-19

BRIEF-J&J Announces Collaboration To Expand Manufacturing Capabilities For Its COVID-19 Vaccine Candidate

* JOHNSON & JOHNSON ANNOUNCES COLLABORATION TO EXPAND MANUFACTURING CAPABILITIES FOR ITS COVID-19 VACCINE CANDIDATE IN SUPPORT OF THE COMPANY'S GOAL TO SUPPLY MORE THAN ONE BILLION VACCINE DOSES GLOBALLY

BRIEF-Emergent Biosolutions Inc - Has Received $14.5 Million From Barda In Support Of Its Covid-Hig Program

* EMERGENT BIOSOLUTIONS PARTNERS WITH U.S. GOVERNMENT FOR COMPREHENSIVE RESPONSE TO EXPEDITE DEVELOPMENT OF PLASMA-DERIVED THERAPY FOR COVID-19

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up